No abstract available
Keywords:
Adjuvant therapy; Adverse events; Immune checkpoint inhibitors; Nivolumab-induced myositis; Nonmetastatic melanoma.
MeSH terms
-
Humans
-
Melanoma* / drug therapy
-
Melanoma* / surgery
-
Melanoma, Cutaneous Malignant
-
Myositis* / chemically induced
-
Myositis* / diagnostic imaging
-
Nivolumab / adverse effects
-
Skin Neoplasms* / drug therapy
-
Skin Neoplasms* / surgery